Abstract B195: Serum levels of CXCL10 and CXCL11 elevate after skin rash induction, the commonest adverse event by bendamustine in the treatment of malignant lymphoma

Abstract

Abstract Introduction: Bendamustine has been recently approved for the treatment of low-grade malignant lymphoma. In spite of the better efficacy, skin rash is the commonest adverse event by bendamustine in the treatment of malignant lymphoma. To understand the mechanism of the skin rash, we prospectively examine the relationship between skin rash and cytokines/chemokines. Methods: After informed consent to the patients, who would received bendamustine (B) or bendmustine+rituximab (BR), the sera were collected before and after the treatment of B or BR. The Cytokine/Chemokine array was performed by Bio-Plex system. Results: 20 patients with FL (n = 18), MCL (n = 1), and low-grade B-cell lymphoma (n = 1) were enrolled in this study. All patients wee treated with B or BR regimen. Nine patients showed skin rash after the treatment of bendamustine. In Cytokine/Chemokine array, serum levels of CCL22 and CCL25 before the treatment were significantly higher in skin rash group (p = 0.010738476 and p = 0.030366028, respectively), and serum levels of CXCL10 and CXCL11 after skin rash were higher significantly (p = 0.000923527 and p = 0.014890795, respectively). Conclusion: The commonest adverse event by bendamustine and CXCL10 and CXCL11might contribute to induction of skin rash by bendamustine, and inhibition of their receptor, CXCR3 may be helpful for the treatment of skin rash by bendamustine Citation Format: Yasuhito Terui, Yuji Mishima, Kiyohiko Hatake. Serum levels of CXCL10 and CXCL11 elevate after skin rash induction, the commonest adverse event by bendamustine in the treatment of malignant lymphoma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B195.